COMT inhibitor

COMT inhibitor je lek koji inhibira dejstvo katehol-O-metil transferaze. Ovaj enzim učestvuje u degradaciji neurotransmitera. COMT inhibitori se koriste u tretmanu Parkinsonove bolesti.

Farmaceutiski članovi ove grupe su između ostalog entakapon,^[1] tolkapon,^[2] i nitekapon. Entakapon ima samo periferno dejstvo, dok su tolkapon i nitekapon aktivni u perifernom i centralnom nervnom sistemu.

Reference

^ Nissinen E; Nissinen H; Larjonmaa H; et al. (2005). „The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats”. J Neural Transm. 112 (9): 1213—1221. PMID 15614425. doi:10.1007/s00702-004-0262-4.
^ Giakoumaki SG, Roussos P, Bitsios P (2008). „Improvement of Prepulse Inhibition and Executive Function by the COMT Inhibitor Tolcapone Depends on COMT Val158Met Polymorphism”. Neuropsychopharmacology. 33 (13): 3058—3068. PMID 18536698. doi:10.1038/npp.2008.82.

[pmid15614425-1] Nissinen E; Nissinen H; Larjonmaa H; et al. (2005). „The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats”. J Neural Transm. 112 (9): 1213—1221. PMID 15614425. doi:10.1007/s00702-004-0262-4.

[pmid18536698-2] Giakoumaki SG, Roussos P, Bitsios P (2008). „Improvement of Prepulse Inhibition and Executive Function by the COMT Inhibitor Tolcapone Depends on COMT Val158Met Polymorphism”. Neuropsychopharmacology. 33 (13): 3058—3068. PMID 18536698. doi:10.1038/npp.2008.82.

[1]

[2]